Considering the beneficial pharmacological effects of each PPAR subtype, a PPAR pan agonist is extremely attractive, especially for the treatment of metabolic syndrome, stroke, heart failure, sudden cardiac death, and certain cancers [52]. Here, PPARA is linked to metabolic syndrome.